These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26890537)

  • 1. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study.
    Lang HC; Lee HC; Lee SS; Lin HY; Chiu YM
    Int J Rheum Dis; 2016 Nov; 19(11):1112-1118. PubMed ID: 26890537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
    Kamata Y; Minota S
    Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
    Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
    J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
    Yang M; Galebach PJ; Signorovitch JE; Garg V
    Clin Exp Rheumatol; 2017; 35(5):791-798. PubMed ID: 28339358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
    Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
    Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
    Popp RA; Rascati K; Davis M; Patel U
    Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
    Chen KC; Wu CH; Tang CH; Huang KC
    PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
    Shi Q; Li KJ; Treuer T; Wang BCM; Gaich CL; Lee CH; Wu WS; Furnback W; Tang CH
    PLoS One; 2018; 13(4):e0193489. PubMed ID: 29624580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
    Tundia N; Kotze PG; Rojas Serrano J; Mendes de Abreu M; Skup M; Macaulay D; Signorovitch J; Chaves L; Chao J; Bao Y
    J Med Econ; 2016 Dec; 19(12):1187-1199. PubMed ID: 27376404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
    Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
    Gu T; Mutebi A; Stolshek BS; Tan H
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
    Tang CH; Yu F; Huang CY; Chen DY
    Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
    Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
    Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.
    Hopkins AM; Vitry AI; O'Doherty CE; Proudman SM; Wiese MD
    Int J Rheum Dis; 2017 Nov; 20(11):1795-1797. PubMed ID: 26176865
    [No Abstract]   [Full Text] [Related]  

  • 19. One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry.
    Fellous S; Rkain H; Ahid S; Abouqal R; Tahiri L; Hmamouchi I; Achemlal L; El Bouchti I; El Maghraoui A; Ghozlani I; Hassikou H; Harzy T; Ichchou L; Mkinsi O; Niamane R; Bahiri R; Allali F
    Rheumatol Int; 2021 Apr; 41(4):787-793. PubMed ID: 33386900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Making smart investment decisions in clinical research.
    Bansback N; Keystone E; O'Dell J; Phibbs CS; Hannagan K; Brophy M; Anis A
    Trials; 2015 Dec; 16():590. PubMed ID: 26712327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.